Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy.
Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretti O, Barbarini G, Marri D, Prestileo T, Dell'Isola S, Rastrelli E, Leo G, Starnini G, Babudieri S, Madeddu G; Gruppo Infettivologi Penitenziari. Pontali E, et al. Among authors: barbarini g. Int J Drug Policy. 2018 Sep;59:50-53. doi: 10.1016/j.drugpo.2018.06.017. Epub 2018 Jul 6. Int J Drug Policy. 2018. PMID: 29986272
Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study.
Barbaro G, Grisorio B, Fruttaldo L, Bacca D, Babudieri S, Torre D, Francavilla R, Rizzo G, Belloni G, Lucchini A, Annese M, Matarazzo F, Hazra C, Barbarini G. Barbaro G, et al. Among authors: barbarini g. BioDrugs. 2003;17(6):433-9. doi: 10.2165/00063030-200317060-00006. BioDrugs. 2003. PMID: 14614766 Clinical Trial.
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates).
Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Almasio PL, et al. Among authors: barbarini g. Dig Liver Dis. 2011 Aug;43(8):589-95. doi: 10.1016/j.dld.2010.12.004. Epub 2011 Jan 21. Dig Liver Dis. 2011. PMID: 21256097
Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Paolucci S, et al. Among authors: barbarini g. Sci Rep. 2017 Nov 22;7(1):16017. doi: 10.1038/s41598-017-15987-1. Sci Rep. 2017. PMID: 29167469 Free PMC article.
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Bertoli A, et al. Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y. Sci Rep. 2018. PMID: 29895871 Free PMC article. Clinical Trial.
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, Tarquini P, Izzi A, Moretti A, Babudieri S, Dell'Isola S, Marignani M, Scifo G, Iovinella V, Cariti G, Pompili M, Candilo FD, Fontanella L, Ettorre GM, Vennarecci G, Ippolito AM, Barbarini G. Pellicelli A, et al. Among authors: barbarini g. Gut Liver. 2020 May 15;14(3):357-367. doi: 10.5009/gnl18269. Gut Liver. 2020. PMID: 30970444 Free PMC article.
Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations.
Paolucci S, Novazzi F, Piralla A, Maserati R, Gulminetti R, Novati S, Barbarini G, Sacchi P, Fratini A, Bellotti L, Baldanti F. Paolucci S, et al. Among authors: barbarini g. Infect Drug Resist. 2019 Jul 8;12:1975-1984. doi: 10.2147/IDR.S205282. eCollection 2019. Infect Drug Resist. 2019. PMID: 31372005 Free PMC article.
114 results